Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies

Main Article Content

Kim Papp
Kristian Reich
Andrew Blauvelt
Diamant Thaci
Rodney Sinclair
Stephen K Tyring
Nicole Cichanowitz
Stuart Green
Qing Li
Carmen La Rosa

Keywords

psoriasis, tildrakizumab, clinical trial

Abstract

Abstract not available.

 

Study supported by Merck & Co., Inc.

Article Sidebar

Poster PDF
Published
Feb 23, 2018
DOI https://doi.org/10.25251/skin.2.supp.4

Article Details

How to Cite
Papp, K., Reich, K., Blauvelt, A., Thaci, D., Sinclair, R., Tyring, S. K., Cichanowitz, N., Green, S., Li, Q., & La Rosa, C. (2018). Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies. SKIN The Journal of Cutaneous Medicine, 2(S1), S4. https://doi.org/10.25251/skin.2.supp.4
Issue
Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Section
Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 2 3 4 5 6 7 8 9 10 11 > >>